Networking and partnerships
We continue to work with local, national, regions and international who have interest with the elimination of viral hepatitis
We drive our mandate from SDG 17 partnerships and collaborations
Creating awareness; We started observing world hepatitis day in 2017 and later in 2018.
We every year join the rest of the globe to commemorate world hepatitis day, we use it to amplify the profile of hepatitis in western rural DIstrict, the nation and beyond via our robust show media platforms
Most people are still ignorant about hepatitis thinking it’s caused by witchcraft and rudimentary Africa monster, we champion efforts in schools, worship place, markets, burials places, and cultural places this is to ensure with break the stigma, reduce barriers to seek diagnosis
Inform masses about the dangers associated with hepatitis and informing them to seek early medical services.
Phylogeny-social support program
We have always interacted with community members diagnosed with hepatitis B .cases of sexual gender-based violence, termination of employment contract, witchcraft accusations and also discrimination
This should not happen, we believe we should have universal health care coverage nobody should be left behind
We strive to use our experience staffs with medical background help us a lot in this endeavor to inform, educate and communicate to families, homes, and communities in the rural western(RWENZORI REGION) Uganda faced with these bottlenecks
Community medical outreaches
Raising awareness creates demand for screening and testing for hepatitis b services
We have been carrying out community outreaches with the aim of finding the missing millions especially rural Uganda population who are undiagnosed with hepatitis b and linking them to health service delivery points
We have done this in markets, worship places schools and corporate companies
Some schools have integrated this in their medical services
Advocacy
We have been at the forefront of the advocacy efforts with meaning engagement with stakeholders lower local government, health sub-district, district health office, regional health administration and ministry of health
Our focus is to continue to join our other CSO’s to ensure more funds are available towards community mobilization and scaling testing to rural communities and linking the diagnosed into care.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close
